Nanjing Cuccess Pharmaceutical

Nanjing Cuccess Pharmaceutical is a Chinese biopharmaceutical company specializing in the development, manufacturing, and commercialization of complex generic drugs, particularly in the fields of peptides, proteins, and polysaccharides. Founded in 2002 and headquartered in Nanjing, the company was acquired by Nanjing Hanxin Pharmaceutical Technology, a subsidiary of the U.S.-based Amphastar Pharmaceuticals, in 2023. Cuccess operates 13 GMP-certified production lines and maintains a diverse portfolio of over 17 commercial products, including insulin glargine, doxofylline, and various antifungal and cardiovascular medications. The company also serves as a CDMO/CMO, providing API production and formulation services for international markets, including the U.S. and Europe. Its research focus leverages advanced technologies in animal extraction, biological fermentation, and enzyme catalysis to produce high-purity active ingredients like PDRN and recombinant proteins.